Biogen (BIIB) Tops Q3 EPS by 31c; raises guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $217.72 +1.57%
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.08, $0.31 better than the analyst estimate of $3.77. Revenue for the quarter came in at $2.47 billion versus the consensus estimate of $2.43 billion.
GUIDANCE:
Biogen sees FY2024 EPS of $16.10-$16.60, versus the consensus of $16.19.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Walmart adds Apple Pay as retailer expands contactless payments
- Peoples Bancorp (PEBK) Declares $0.21 Quarterly Dividend; 1.9% Yield
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
